-continued

oligonucleotide

<400> SEQUENCE: 16

aacauucauu gcugucggug ggu 23

<210> SEQ ID NO 17
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

<400> SEQUENCE: 17

agcactttct cccggccgcc atggccgcgg gat 33

<210> SEQ ID NO 18
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

<400> SEQUENCE: 18

atttgcacct cccggccgcc atggccgcgg gat 33

<210> SEQ ID NO 19
<211> LENGTH: 39
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

<400> SEQUENCE: 19

uugccaugug uaugugggcu uacgcugagu acuucgauu 39

1. An artificial RNA nanostructure molecule, wherein the molecule comprises a multiple branched RNA junction motif comprising at least one RNA oligonucleotide, and a brain tumor targeting module, wherein the module is coupled to an RNA junction motif.

2. The molecule of claim **1** further comprising at least one bioactive agent coupled to the RNA junction motif.

3. (canceled)

4. The molecule of claim **1**, wherein the RNA oligonucleotide comprises at least one chemical modification at the 2' position.

5. The molecule of claim **4**, wherein the modification comprises 2' Fluoro, 2' Amine, 2' O-Methyl, or a combination thereof.

6. The molecule of claim **1**, wherein the motif is a three-branched RNA junction motif.

7. (canceled)

8. The molecule of claim **1**, wherein the diameter of the molecule is at least about 40 nm or less.

9. (canceled)

10. (canceled)

11. The molecule of claim **1**, wherein the molecule has a zeta potential ranging from about −50 m V to about 50 m V.

12. (canceled)

13. The molecule of claim **1**, wherein the multiple branched RNA comprises a nucleotide sequence 5'-UUG CCA UGU GUA UGU GGG AUC CCG CGG CCA UGG CGG CCG GGA G-3' (SEQ ID NO: 6) or 5'-GATAAGCT CTC CCG GCC GCC ATG GCC GCG GGA T-3' (SEQ ID NO: 7).

14. (canceled)

15. The molecule of claim **6**, wherein a branch of the three-branched RNA junction motif comprises an a3WJ RNA module (SEQ ID NO: 1); a b3WJ RNA module (SEQ ID NO: 2); a c3WJ RNA module (SEQ ID NO: 3); or a combination thereof.

16. (canceled)

17. The molecule of claim **1**, wherein RNA oligonucleotides comprises at least 6 nucleotides in length.

18. (canceled)

19. (canceled)

20. (canceled)

21. The molecule of claim **1**, wherein the brain tumor targeting module comprises a ligand that binds to at least one brain tumor cell surface marker.

22. The molecule of claim **21**, wherein the ligand binds to a folate receptor, an EGFR, a transferrin receptor, an RGD, or a combination thereof.